Business
AstraZeneca COVID-19 vaccine trial data results in revised efficacy rate
The Oxford-AstraZeneca PLC (LON: AZN) COVID-19 vaccine has travelled a bumpy road through its development and rollout. Marred with accusations of the vaccine causing blood clots, regulatory and government pressures have weighed on the drug developer and its acceptance.
According to the latest press release from AstraZeneca, the company has revised the vaccine’s efficacy from 79% to 76%, following further analysis with an additional 49 symptomatic COVID-19 cases.
Details of the COVID-19 vaccine findings
After scrutiny from the US National Institute of Allergy and Infectious Diseases for purportedly out-of-date data in the original…
-
Noosa News14 hours agoTwo in five Brisbane streets have no footpaths, with council building about 4km of new paths last year
-
Business23 hours agoWhere to invest $20,000 in ASX ETFs for 2026 and beyond
-
General22 hours agoReece Walsh grabs the Sun to lead Brisbane to an all-time victory over Canberra
-
General21 hours agoBritish boxer and former world champion Ricky Hatton dies at age 46